Spider-Man is one of the most popular superheroes ever created, and just like others, this character had several adaptations for the big screen. It started with the original ‘Spider-Man’ movie ...

Spider-Man 4 will be a "fresh start" for Peter Parker, according to star Tom Holland, so forget everything you know about the character and get ready for a brand-new MCU adventure. The film, which ...

Incyte (NASDAQ:INCY) recently announced that it had achieved positive results from both of its phase 3 studies STOP-HS1 and STOP-HS2. Both of these late-stage studies were using the company's drug ...

Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral small-molecule JAK1 inhibitor, povorcitinib, for the treatment of hidradenitis ...

Wells Fargo analyst Derek Archila maintained a Hold rating on Incyte (INCY – Research Report) yesterday and set a price target of $58.00. The company’s shares closed yesterday at $62.01.

On Wednesday, RBC Capital adjusted its outlook on CrowdStrike Holdings (NASDAQ:CRWD), increasing the price target to $420 from the ...

Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY) fell 15.2% in the pre-market session after the company released phase three trial data for a skin condition treatment ...

Spider-Man is one of the few Marvel heroes with a supporting cast and rogues gallery wide enough to support an entire cinematic universe. Or so execs at Sony thought when they launched their ...

Incyte Corp (NASDAQ:INCY) stock is down 11.4% to trade at $60.16 at last glance, after the pharmaceutical company's phase three trial data for its skin disease treatment showed it was only ...